A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy
Latest Information Update: 16 Dec 2024
At a glance
- Drugs Upadacitinib (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Acronyms Viti-Up
- Sponsors AbbVie
- 11 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2024 Planned End Date changed from 7 Feb 2028 to 5 Feb 2028.
- 20 Mar 2024 Planned primary completion date changed from 7 Nov 2025 to 23 Feb 2027.